A first‑in‑human study of the c‑Met‑targeting antibody‑drug conjugate Temab‑A (ABBV‑400) has sparked optimism for patients with metastatic colorectal cancer (mCRC) who have exhausted standard options. In the multicenter Phase I trial (NCT05029882), 179 heavily pre‑treated patients with solid tumours – including 122 with mCRC – received Temab‑A at escalating doses every three weeks. The trial identified 3.0 mg/kg as the maximum tolerated dose and moved into a dose‑expansion cohort of 93 mCRC patients with BRAF‑wild‑type, microsatellite‑stable disease. Across the study, patients had received a median of four prior therapy lines, yet the drug demonstrated manageable safety and early signs of anti‑tumour activity, offering a potential new third‑line option where response rates are traditionally low. The report also highlighted complementary advances: a Chinese Phase II trial showing survival benefits from a triple regimen of irinotecan, TAS‑102 and bevacizumab; and immunotherapy data where nivolumab plus ipilimumab prolonged progression‑free survival in MSI‑H mCRC. Together, these findings underscore a growing arsenal of targeted and immune‑based strategies aimed at extending life and improving quality of care for patients facing advanced colorectal cancer.
Read moreA wave of fresh data is reshaping how doctors treat metastatic colorectal cancer (mCRC). The most eye‑catching development is Temab‑A, a novel antibody‑drug conjugate that homes in on the c‑Met protein and is being tested as a third‑line option for patients whose disease has progressed despite standard therapies. Early results suggest meaningful tumor shrinkage with manageable side effects. In China, a Phase II trial (NCT06202001) found that a three‑drug cocktail—irinotecan, TAS‑102, and bevacizumab—provided a clear survival advantage for patients who had their primary tumor removed, positioning it as a strong second‑line candidate. Immunotherapy also made headlines: the CheckMate 8HW study showed that combining nivolumab with ipilimumab dramatically extended progression‑free survival in MSI‑H/dMMR mCRC patients who had not yet received systemic treatment. Another promising regimen pairs the checkpoint inhibitor SHR‑1701 with XELOX chemotherapy and bevacizumab, delivering robust responses and tolerable safety in first‑line, unresectable mCRC. Conversely, the ORCHESTRA randomized trial confirmed that adding extensive tumor‑removing surgery to palliative chemotherapy does **not** improve overall survival for multi‑organ metastatic disease. Finally, cutting‑edge liquid‑biopsy work demonstrated that serial ctDNA monitoring can predict early chemotherapy response, while a real‑world case highlighted the durability of trifluridine/tipiracil (FTD/TPI) over nearly three years as a third‑line option. Together, these studies offer renewed optimism and clearer pathways for patients battling advanced colorectal cancer.
Read moreA wave of fresh research is reshaping how doctors treat metastatic colorectal cancer, the most aggressive form of colon cancer. A Chinese Phase II trial (NCT06202001) tested a three‑drug combo – irinotecan, TAS‑102 and bevacizumab – as a second‑line option and found that patients who had their primary tumor removed lived longer than expected. Meanwhile, the CheckMate 8HW study showed that pairing two immune‑checkpoint drugs, nivolumab and ipilimumab, dramatically slowed disease progression in patients whose tumors have a specific DNA‑repair defect (MSI‑H/dMMR), outperforming standard chemotherapy. In a separate breakthrough, the antibody‑drug conjugate Temab‑A, which homes in on the c‑Met protein, demonstrated promising activity as a third‑line treatment, giving patients another lifeline after other therapies fail. Another novel agent, SHR‑1701, combined with standard chemotherapy (XELOX) and bevacizumab, shrank tumors by more than 30 % in 60 % of participants, suggesting a new avenue for first‑line therapy. A JAMA‑published ORCHESTRA trial, however, warned that aggressive surgery plus chemotherapy does not improve survival for patients with widespread organ metastases. On the bright side, a real‑world case showed a patient responding to trifluridine/tipiracil (FTD/TPI) for nearly three years, highlighting its durability as a third‑line option. Finally, researchers proved that tracking circulating tumor DNA can predict how well first‑line chemo works, paving the way for more personalized treatment decisions. Together, these studies signal a rapidly expanding toolbox against a disease that has long needed new hope.
Read more